Vtesse Company
Vtesse's lead compound, VTS-270, has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease.
Employee Number:
11-50
Funding Status:
M&A
Headquarters:
Gaithersburg, Maryland, United States
Technology:
Others
Estimated Revenue:
$1M to $10M
Founded Date:
2014
Industry:
PharmTech